로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > LRP-5

LRP-5

요약

Name:Low-density lipoprotein receptor-related protein 5
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

제품 리스트 구매

일부의 생물활성 데이터

LR5-H5254-ELISA
 LRP-5 ELISA

Immobilized Biotinylated Human Dkk-1, Fc,Avitag (Cat. No. DK1-H82F5) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human LRP-5, Mouse IgG2a Fc Tag (Cat. No. LR5-H5254) with a linear range of 1-31 ng/mL (QC tested).

Synonym Name

LRP5,LRP-5,LRP-7,LRP7,LR3

Background

Low-density lipoprotein receptor-related protein 5(LRP-5) is also known as  BMND1, EVR1, EVR4, HBM, LR3, LRP7, OPPG, OPTA1, VBCH2, LDL receptor related protein 5 and PCLD4. LRP5 is a transmembrane low-density lipoprotein receptor that shares a similar structure with LRP6. LRP5 acts as a co-receptor with LRP6 and the Frizzled protein family members for transducing signals by Wnt proteins through the canonical Wnt pathway. This protein plays a key role in skeletal homeostasis. Mutations in LRP5 can lead to considerable changes in bone mass. A loss-of-function mutation causes osteoporosis-pseudoglioma (decrease in bone mass), while a gain-of-function mutation causes drastic increases in bone mass.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
BI-905681 BI-905681 Phase 1 Clinical Boehringer Ingelheim Ltd Neoplasms Details
BI-905681 BI-905681 Phase 1 Clinical Boehringer Ingelheim Ltd Neoplasms Details

This web search service is supported by Google Inc.

totop